Literature DB >> 26311860

Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.

Riad Khatib1, Kathleen Riederer2, Mamta Sharma2, Stephen Shemes2, Sugantha P Iyer2, Susan Szpunar2.   

Abstract

BHI agars supplemented with vancomycin 4 (BHI-V4) and 3 (BHI-V3) mg/liter have been proposed for screening vancomycin intermediately susceptible Staphylococcus aureus (VISA) and heteroresistant (hVISA) phenotypes, respectively, but growth interpretation criteria have not been established. We reviewed the growth results (CFU) during population analysis profile-area under the curve (PAP-AUC) of consecutive methicillin-resistant Staphylococcus aureus (MRSA) blood isolates, which were saved intermittently between 1996 and 2012. CFU counts on BHI-V4 and BHI-V3 plates were stratified according to PAP-AUC interpretive criteria: <0.90 (susceptible [S-MRSA]), 0.90 to 1.3 (hVISA), and >1.3 (VISA). CFU cutoffs that best predict VISA and hVISA were determined with the use of receiver operating characteristic (ROC) curves. Mu3, Mu50, and methicillin-susceptible S. aureus (MSSA) controls were included. We also prospectively evaluated manufacturer-made BHI-V3/BHI-V4 biplates for screening of 2010-2012 isolates. The PAP-AUC of 616 clinical samples was consistent with S-MRSA, hVISA, and VISA in 550 (89.3%), 48 (7.8%), and 18 (2.9%) instances, respectively. For VISA screening on BHI-V4, a cutoff of 2 CFU/droplet provided 100% sensitivity and 97.7% specificity. To distinguish VISA from hVISA, a cutoff of 16 CFU provided 83.3% sensitivity and 94.7% specificity; the specificity was lowered to 89.5% with a 12-CFU cutoff. For detecting hVISA/VISA on BHI-V3, a 2-CFU/droplet cutoff provided 98.5% sensitivity and 93.8% specificity. These results suggest that 2-CFU/droplet cutoffs on BHI-V4 and BHI-V3 best approximate VISA and hVISA gold standard confirmation, respectively, with minimal overlap in samples with borderline PAP-AUC. Simultaneous screening for VISA/hVISA on manufacturer-made BHI-V4/BHI-V3 biplates is easy to standardize and may reduce the requirement for PAP-AUC confirmation.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26311860      PMCID: PMC4609695          DOI: 10.1128/JCM.01620-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

2.  A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.

Authors:  Mandy Wootton; Alasdair P MacGowan; Timothy R Walsh; Robin A Howe
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

3.  Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Pamela A Moise; George Sakoulas; Alan Forrest; Jerome J Schentag
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

4.  Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.

Authors:  Patrick G P Charles; Peter B Ward; Paul D R Johnson; Benjamin P Howden; M Lindsay Grayson
Journal:  Clin Infect Dis       Date:  2004-01-12       Impact factor: 9.079

5.  Heteroresistance: a concern of increasing clinical significance?

Authors:  M E Falagas; G C Makris; G Dimopoulos; D K Matthaiou
Journal:  Clin Microbiol Infect       Date:  2007-12-18       Impact factor: 8.067

6.  Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin.

Authors:  T P Lodise; J Graves; A Evans; E Graffunder; M Helmecke; B M Lomaestro; K Stellrecht
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

7.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Alex Soriano; Francesc Marco; José A Martínez; Elena Pisos; Manel Almela; Veselka P Dimova; Dolores Alamo; Mar Ortega; Josefina Lopez; Josep Mensa
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

8.  Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Amir Khosrovaneh; Kathleen Riederer; Sajjad Saeed; M Shamse Tabriz; Amar R Shah; Michel M Hanna; Mamta Sharma; Leonard B Johnson; Mohammad G Fakih; Riad Khatib
Journal:  Clin Infect Dis       Date:  2004-04-14       Impact factor: 9.079

9.  Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.

Authors:  Margaret M Fitzgibbon; Angela S Rossney; Brian O'Connell
Journal:  J Clin Microbiol       Date:  2007-08-08       Impact factor: 5.948

10.  A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).

Authors:  Andreas Voss; Johan W Mouton; Erika P van Elzakker; Ron G Hendrix; Wil Goessens; Jan A Kluytmans; Paul F Krabbe; Han J de Neeling; Jacobus H Sloos; Nefise Oztoprak; Robin A Howe; Timothy R Walsh
Journal:  Ann Clin Microbiol Antimicrob       Date:  2007-09-24       Impact factor: 3.944

View more
  4 in total

1.  Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.

Authors:  Betsy E Castro; Maritza Berrio; Monica L Vargas; Lina P Carvajal; Lina V Millan; Rafael Rios; Angie K Hernandez; Sandra Rincon; Paola Cubides; Erika Forero; An Dinh; Carlos Seas; Jose M Munita; Cesar A Arias; Jinnethe Reyes; Lorena Diaz
Journal:  J Antimicrob Chemother       Date:  2020-09-01       Impact factor: 5.790

2.  Nasal Carriage by Staphylococcus aureus among Healthcare Workers and Students Attending a University Hospital in Southern Brazil: Prevalence, Phenotypic, and Molecular Characteristics.

Authors:  Tiago Danelli; Felipe Crepaldi Duarte; Thilara Alessandra de Oliveira; Raquel Soares da Silva; Daniela Frizon Alfieri; Guilherme Bartolomeu Gonçalves; Caio Ferreira de Oliveira; Eliandro Reis Tavares; Lucy Megumi Yamauchi; Marcia Regina Eches Perugini; Sueli Fumie Yamada-Ogatta
Journal:  Interdiscip Perspect Infect Dis       Date:  2020-12-03

3.  Vancomycin heteroresistance in Staphylococcus haemolyticus: elusive phenotype.

Authors:  Yamuna Devi Bathavatchalam; Dhanalakshmi Solaimalai; Anushree Amladi; Hariharan Triplicane Dwarakanathan; Shalini Anandan; Balaji Veeraraghavan
Journal:  Future Sci OA       Date:  2021-04-09

4.  Genomic insights on heterogeneous resistance to vancomycin and teicoplanin in Methicillin-resistant Staphylococcus aureus: A first report from South India.

Authors:  Yamuna Devi Bakthavatchalam; Priyanka Babu; Elakkiya Munusamy; Hariharan Triplicane Dwarakanathan; Priscilla Rupali; Marcus Zervos; Peter John Victor; Balaji Veeraraghavan
Journal:  PLoS One       Date:  2019-12-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.